Autoimmune And Rheumatic Diseases
Listen up: Healio Rheuminations explored medical histories and mysteries in 2024
Is there “rheum” for one more podcast in your life?
A part-time retirement to rural medicine: When work becomes joy
We are again privileged to have rheumatologist and author Chuck Radis, DO, grace the pages of Healio Rheumatology with his continuing observations on the life of those who are lucky enough to be in our little club of practitioners.
Premature death from rheumatoid arthritis in Native Americans has not improved in 20 years
WASHINGTON — High rates of premature mortality from rheumatoid arthritis among Native American populations have seen no change in the past 20 years, while other races have demonstrated improving trends, according to data.
Rising placebo response rates in rheumatoid arthritis trials mirror recruitment shifts
WASHINGTON — Rising rates of ACR20 response in the placebo arms of rheumatoid arthritis trials may be related to increasingly globalized recruitment patterns, according to data presented at ACR Convergence 2024.
GPT-4’s rheumatology answers more accurate vs other LLMs, still have ‘possibility of harm'
WASHINGTON — Despite answering 78% of rheumatology questions correctly, besting two other popular large language models, GPT-4 nonetheless introduced the “possibility of harm” in up to 20% of its responses, according to data.
CAR T therapy shows ‘no major hematotoxicites’ in autoimmune disease phase 1/2 study
WASHINGTON — A phase 1/2 study of CD19 chimeric antigen receptor T-cell therapy in lupus and other autoimmune diseases demonstrated significant response with minimal toxicities, according to data presented at ACR Convergence 2024.
CD19 CAR-T therapy yields long-term benefits in lupus, myositis, systemic sclerosis
WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over a period of up to 15 months in 35 patients with lupus, myositis and systemic sclerosis, according to data.
Medication-assisted weight loss boosts patient-reported outcomes in rheumatic disease
WASHINGTON — Patients who use medication or surgery to achieve at least 5% weight loss demonstrate greater improvements in patient-reported outcomes across various rheumatic diseases, according to data presented at ACR Convergence 2024.
Mortality similar after single- vs double-lung transplant in autoimmune disease with ILD
WASHINGTON — Patients with systemic autoimmune rheumatic disease who develop interstitial lung disease demonstrate similar 1-year mortality risks following either single- or double-lung transplant, according to data.
Severe infection, rituximab use predict long COVID in patients with autoimmune disease
WASHINGTON — Severe acute COVID-19 infection, as well as glucocorticoid and rituximab use, increase the risk for long COVID in patients with autoimmune rheumatic diseases, according to data presented at ACR Convergence 2024.